NASDAQ · TTRX
Healthcare · Biotechnology
$13.72
Up+$0.26 (+1.93%)
Updated Sep 16, 2026, 10:16 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TTRX closed at $13.72 after 21 trading sessions, up 37.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $13.46 | $14.21 | $13.40 | $13.72 | 150.34K |
| Sep 15, 2026 | $13.37 | $13.85 | $13.215 | $13.46 | 85.17K |
| Sep 14, 2026 | $12.43 | $13.82 | $12.11 | $13.45 | 131.46K |
| Sep 11, 2026 | $13.30 | $14.25 | $12.63 | $12.69 | 135.66K |
| Sep 10, 2026 | $13.34 | $14.2899 | $13.03 | $13.38 | 125.08K |
| Sep 9, 2026 | $12.61 | $14.39 | $12.58 | $13.75 | 277.54K |
| Sep 8, 2026 | $9.99 | $12.6786 | $9.82 | $12.66 | 321.76K |
| Sep 4, 2026 | $9.975 | $10.50 | $9.70 | $9.80 | 70.57K |
| Sep 3, 2026 | $9.67 | $10.4999 | $9.67 | $10.07 | 82.47K |
| Sep 2, 2026 | $9.70 | $10.25 | $9.00 | $9.67 | 106.48K |
| Sep 1, 2026 | $9.60 | $10.285 | $9.28 | $9.82 | 43.21K |
| Aug 31, 2026 | $9.83 | $10.25 | $9.50 | $9.60 | 31.64K |
| Aug 28, 2026 | $10.10 | $10.275 | $9.47 | $9.84 | 62.76K |
| Aug 27, 2026 | $9.54 | $10.25 | $9.51 | $10.11 | 47.6K |
| Aug 26, 2026 | $10.035 | $10.035 | $9.45 | $9.63 | 69.36K |
| Aug 25, 2026 | $9.78 | $10.035 | $9.58 | $9.73 | 31.39K |
| Aug 24, 2026 | $9.39 | $9.87 | $9.04 | $9.68 | 70.26K |
| Aug 21, 2026 | $9.635 | $9.925 | $9.35 | $9.46 | 22.23K |
| Aug 20, 2026 | $9.945 | $10.03 | $9.52 | $9.54 | 32K |
| Aug 19, 2026 | $9.745 | $10.18 | $9.71 | $9.82 | 26.82K |
| Aug 18, 2026 | $9.75 | $10.105 | $9.745 | $9.99 | 20.39K |
The latest Smart Investors Daily articles mentioning TTRX.
TTRX research
Company profile and research snapshot.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | WBB Securities | Sell | — |
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
| Dec 29, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
WESTLAKE VILLAGE, Calif., September 09, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer.
Yahoo · Sep 8, 2026
Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value
Benzinga · Aug 20, 2026
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
SeekingAlpha · Jul 15, 2026
Turn Therapeutics offers high risk-reward potential, hinging entirely on its late-stage asset GX-03 for Eczema and Onychomycosis. Click for more on TTRX stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TTRX.
